Search

Your search keyword '"3-O-Desacyl-4'-Monophosphoryl Lipid A"' showing total 3 results
Start Over Descriptor "3-O-Desacyl-4'-Monophosphoryl Lipid A"
3 results on '"3-O-Desacyl-4'-Monophosphoryl Lipid A"'

1. Development and Evaluation of AS04, a Novel and Improved Adjuvant System Containing 3-O-Desacyl-4′- Monophosphoryl Lipid A and Aluminum Salt

Author

F. Tavares Da Silva and Nathalie Garçon

Subjects
business.industry, medicine.medical_treatment, Antibody titer, Monophosphoryl Lipid A, complex mixtures, 03 medical and health sciences, 0302 clinical medicine, Immunity, 030220 oncology & carcinogenesis, Immunology, medicine, 030212 general & internal medicine, business, Adjuvant, 3-O-Desacyl-4'-Monophosphoryl Lipid A
Abstract

During the past two decades, GSK Vaccines has been developing new Adjuvant Systems (ASs) intended to promote a faster, stronger, and longer protection through the induction of high and persistent antibody titer and induction of cell-mediated immunity (CMI). One such proprietary AS, AS04, has been developed for prophylactic vaccines. AS04 is composed of two adjuvants: aluminum salt and 3-O-desacyl-4′- monophosphoryl lipid A (MPL).

Published
2017
Full Text
View/download PDF

2. Predictive markers of safety and immunogenicity of adjuvanted vaccines.

Author

Mastelic B, Garçon N, Del Giudice G, Golding H, Gruber M, Neels P, and Fritzell B

Subjects
Animals, Antibody Formation immunology, Humans, Models, Animal, Patient Outcome Assessment, Vaccination methods, Adjuvants, Immunologic therapeutic use, Vaccines immunology, Vaccines therapeutic use
Abstract

Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been included in vaccine preparations to boost the immune responses through different mechanisms. Although a variety of novel adjuvants have been under development, only a limited number have been approved by regulatory authorities for human vaccines. This report reflects the conclusions of a group of scientists from academia, regulatory agencies and industry who attended a conference on the current state of the art in the adjuvant field. Held at the U.S. Pharmacopeial Convention (USP) in Rockville, Maryland, USA, from 18 to 19 April 2013 and organized by the International Association for Biologicals (IABS), the conference focused particularly on the future development of effective adjuvants and adjuvanted vaccines and on overcoming major hurdles, such as safety and immunogenicity assessment, as well as regulatory scrutiny. More information on the conference output can be found on the IABS website, http://www.iabs.org/., (Copyright © 2013. Published by Elsevier Ltd.. All rights reserved.)

Published
2013
Full Text
View/download PDF

3. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.

Author

Nelson EA, Lam HS, Choi KC, Ho WC, Fung LW, Cheng FW, Sung RY, Royals M, and Chan PK

Subjects
Adolescent, Adult, Antibodies, Neutralizing blood, Antibodies, Viral blood, Antibody Formation, Dose-Response Relationship, Immunologic, Female, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Humans, Injections, Intradermal, Injections, Intramuscular, Male, Middle Aged, Neutralization Tests, Papillomavirus Vaccines adverse effects, Papillomavirus Vaccines immunology, Pilot Projects, Young Adult, Papillomavirus Vaccines administration & dosage, Vaccination methods
Abstract

Intradermal administration of human papillomavirus (HPV) vaccines could be dose-sparing and cost-saving. This pilot randomized study assessed Cervarix(®) and Gardasil(®) administered either intramuscularly or intradermally, in different doses (full-dose or reduced to 20%) by different methods (needle and syringe or PharmaJet needle-free jet injection device). Following an initial reactogenicity study of 10 male subjects, sexually naïve women aged 18-26 years were randomized to the eight study groups to receive vaccine at 0, 2 and 6 months. 42 female subjects were enrolled and complete data were available for 40 subjects. Intradermal administration of either vaccine raised no safety concerns but was more reactogenic than intramuscular administration, although still tolerable. All subjects demonstrated a seroconversion (titre≥1:320) by Day 95. Further evaluation of intradermal HPV vaccination and its potential for cost reduction in resource poor settings is warranted., (Copyright © 2013 Elsevier Ltd. All rights reserved.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results